- |||||||||| budesonide / Generic mfg.
Journal: Trends in contact sensitization, results, and implications from a contact dermatitis clinic in Israel. (Pubmed Central) - May 2, 2024
While among the EBS, NIPPD, Propolis, Sesquiterpene lactone, and Budesonide usually do not elicit a positive reaction and therefore should be reconsidered in baseline series, among the OEBS, Chloramphenicol, Quaternium 15, Propyl gallate, and Amerchol L101 have elicited high SPIN values and should be vigilantly examined in the suitable clinical scenario. Significantly lower sensitization frequency to propolis raises the possibility of a protective effect due to early oral exposure among the Israeli population.
- |||||||||| budesonide / Generic mfg.
Journal: Follow-Up of Microscopic Colitis Patients and Diarrhea Controls at 1 Year. (Pubmed Central) - Apr 29, 2024
In a cohort of patients with biopsy-confirmed MC and diarrhea controls, we found that some cases remained unaware of their diagnosis, many cases had persistent symptoms, and controls had worse symptoms than cases. These findings suggest there are opportunities to improve management of this chronic disease.
- |||||||||| Dupixent (dupilumab) / Sanofi, Regeneron
Review, Journal: Diagnosis, management and therapeutic options for eosinophilic esophagitis. (Pubmed Central) - Apr 24, 2024
In addition, exploring the coexistence or the previous occurrence of other type 2 conditions may suggest the opportunity to specifically target type 2 inflammation through biologic therapy. The complex EoE pathobiology combining inflammatory and functional features, both at organ and systemic level, requires a multidimensional approach relying on the strict integration of gastroenterologists and allergist-immunologists.
- |||||||||| Xifaxan (rifaximin) / Alfa Wassermann, Bausch Health
Clinical and atopic features of patients with primary eosinophilic colitis: an Italian multicentre study (Poster Zone) - Apr 21, 2024 - Abstract #EAACI2024EAACI_2689;
The complex EoE pathobiology combining inflammatory and functional features, both at organ and systemic level, requires a multidimensional approach relying on the strict integration of gastroenterologists and allergist-immunologists. Therapeutical agents prescribed in patients with EC were as follows: rifaximin (n=4, 10%), mesalazine (n=15, 37.5%), probiotics (n=10, 25%), budesonide (n=16, 60%), systemic corticosteroids (n=5, 12.5%), antidiarrheal agents (n=8, 20%), combination therapy (budesonide
- |||||||||| budesonide / Generic mfg.
Enrollment open, Head-to-Head: Budesonide versus prednisolone after liver transplantation: a phase 3, open label, non-inferiority randomised controlled trial (EUDRACT) - Apr 19, 2024
P3, N=100, Recruiting,
Therapeutical agents prescribed in patients with EC were as follows: rifaximin (n=4, 10%), mesalazine (n=15, 37.5%), probiotics (n=10, 25%), budesonide (n=16, 60%), systemic corticosteroids (n=5, 12.5%), antidiarrheal agents (n=8, 20%), combination therapy (budesonide Not yet recruiting --> Recruiting
- |||||||||| budesonide / Generic mfg.
Analysis of Positive Patch Test Allergens in Allergic Contact Dermatitis Patients with Atopic Dermatitis (E-TPS Display Only Digital section) - Apr 5, 2024 - Abstract #EAACI2024EAACI_393;
The positivity rate for budesonide was significantly higher in the AD group (p=0.011), while the prevalence of a positive result for balsam of Peru was higher in the non-AD group (p=0.036)...Conclusion Our study shows a decreased prevalence of contact sensitization in AD patients compared to non-AD patients. Clinicians should be aware of the risk of corticosteroid allergies in ACD patients with history of AD.
- |||||||||| montelukast/mometasone (MK 0476C) / Merck (MSD)
Retrospective data, Review, Journal: Pharmacological interventions for pediatric obstructive sleep apnea (OSA): Network meta-analysis. (Pubmed Central) - Mar 25, 2024
The combination of mometasone furoate nasal spray and oral montelukast sodium exhibits the highest probability of being the most effective intervention. Further research is needed to investigate the long-term efficacy and safety profiles of these interventions in pediatric patients with OSA.
- |||||||||| Rituxan (rituximab) / Roche
Review, Journal: Treatment of autoimmune hepatitis-First-line, second-line and third-line treatment (Pubmed Central) - Mar 25, 2024
For patients who do not achieve biochemical remission through first-line or second-line treatment, a variety of medications are available for third-line treatment, e.g., rituximab, calcineurin inhibitors or antitumor necrosis factor (anti-TNF) antibodies. Third-line treatment should be carried out in expert centers and registered in the European Reference Network for Rare Liver Diseases in order to improve the currently sparse database for these forms of treatment in the future.
- |||||||||| Filspari (sparsentan) / Travere Therap, sibeprenlimab (VIS649) / Otsuka
Review, Journal: Immunoglobulin (Pubmed Central) - Mar 25, 2024
Third-line treatment should be carried out in expert centers and registered in the European Reference Network for Rare Liver Diseases in order to improve the currently sparse database for these forms of treatment in the future. While systemic corticosteroids are now only indicated in rare cases, a
- |||||||||| Filspari (sparsentan) / Travere Therap
Navigating Uncharted Waters: Management of IgA Nephropathy with combined Budesonide and Sparsentan () - Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_648;
The rationale of using both therapies is to maximize inhibition of the renin-angiotensin system and endothelin-1 blockade while reducing galactose-deficient IgA1 production in the Peyer's patches of the gut, an essential link in the 4-hit hypothesis of IgAN. Clinically, we observed an additive effect on proteinuria with minimal side effects.
- |||||||||| budesonide / Generic mfg.
Observational data, Retrospective data, Journal: The association between drugs and repeated treatment with budesonide in patients with microscopic colitis: a retrospective observational study. (Pubmed Central) - Mar 21, 2024
No association was seen between being a smoker and/or being prescribed NSAID, ASA, PPI, SSRI, and statins at baseline and the odds of having a prescription of oral budesonide within 1 year after diagnosis. The risk of being prescribed a second course of budesonide is associated with receiving a prescription of NSAIDs but not with the use of ASA, PPIs, SSRIs, and statins.
- |||||||||| Filspari (sparsentan) / Travere Therap, CSL Behring
Journal: New therapies for immunoglobulin A nephropathy: what's the standard of care in 2023? (Pubmed Central) - Mar 20, 2024
Numerous therapeutic options now exist and include disease-modifying and nephroprotective drugs. Identifying the right treatment for the right patient is now the clinical challenge and, with new drugs on the horizon, represents the primary unmet research need in this rapidly-developing field.
- |||||||||| Remicade (infliximab) / J&J, Rituxan (rituximab) / Roche
Journal: Advancements in autoimmune hepatitis management: Perspectives for future guidelines. (Pubmed Central) - Mar 18, 2024
However, these interesting findings have yet to be replicated by other research groups. Additionally, second-line drugs, such as tacrolimus, rituximab, and infliximab, should be subjected to controlled trials for further evaluation.
- |||||||||| Review, Journal: Allergic Rhinitis: A Review. (Pubmed Central) - Mar 16, 2024
Patients with allergic rhinitis should be instructed to avoid inciting allergens. Therapies include second-generation H1 antihistamines (eg, cetirizine, fexofenadine, desloratadine, loratadine), intranasal antihistamines (eg, azelastine, olopatadine), and intranasal corticosteroids (eg, fluticasone, triamcinolone, budesonide, mometasone) and should be selected based on the severity and frequency of symptoms and patient preference.
- |||||||||| OPEN-CAPSULE BUDESONIDE FOR THE TREATMENT OF IMMUNE-RELATED ENTERITIS FROM CHECKPOINT INHIBITORS (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_7491;
OCB avoids systemic immunosuppression and was successful at inducing and maintaining clinical response and remission even in patients with prior inadequate response to systemic corticosteroids and biologic agents. We suggest OCB's optimal place in treatment algorithms is for patients presenting with high clinical suspicion for irEnteritis such as predominant upper GI symptoms including anorexia, early satiety, nausea, vomiting and diarrhea, ideally with endoscopic and/or histologic confirmation of enteritis.
- |||||||||| THE EFFECTIVENESS OF BUDESONIDE ONCE DAILY AS MAINTENANCE TREATMENT FOR EOSINOPHILIC ESOPHAGITIS: A RETROSPECTIVE ANALYSIS. (Hall A, Poster Hall - Walter E. Washington Convention Center) - Mar 14, 2024 - Abstract #DDW2024DDW_955;
Both once daily oral mesalamine monotherapy (MES) and the combination of once daily oral mesalamine and rectal budesonide suppository (MES/BUS) are effective treatments for active UC, but resolution of symptoms and clinical improvement is accomplished more rapidly with the combination therapy. In this retrospective study, we demonstrated favorable histological and clinical results in the majority of patients of once daily dosing of 1mg budesonide during maintenance treatment of eosinophilic esophagitis.
- |||||||||| budesonide / Generic mfg.
Review, Journal: Diagnosing and Treating IgAN: Steroids, Budesonide, or Maybe Both? (Pubmed Central) - Mar 13, 2024
Targeted-release budesonide is a therapeutic modality that aims to inhibit disease pathogenetic pathways at early stages; it has minor systemic absorption and proven beneficial effects on renal function and proteinuria. In the present systemic review, the benefits and adverse events of steroids and budesonide are described, and the possibility of combined treatment is questioned in selected cases with active histologic lesions.
- |||||||||| budesonide / Generic mfg., ipratropium bromide / Generic mfg.
Retrospective data, Journal: Probiotics combined with Budesonide and Ipratropium bromide for chronic obstructive pulmonary disease: A retrospective analysis. (Pubmed Central) - Mar 12, 2024
After treatment, the levels of lactobacilli and bifidobacteria in the 2 groups increased compared to those before treatment, and the observation group had a higher level, while the levels of Enterobacteriaceae and Enterococcus were lower in the observation group than those before treatment (P?<?.05). Based on budesonide and irpratropium bromide, probiotic treatment of COPD is more conducive to reducing the degree of inflammatory reactions, inhibiting airway remodeling, regulating the level of gut microbiota, and promoting the recovery of lung function.
- |||||||||| Filspari (sparsentan) / Travere Therap
Improved Proteinuria Reduction with the use of Sparsentan and Targeted Release Budesonide in advanced IgAN (TUE-075; Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_952;
This serves as a surrogate marker for improved kidney function and outcomes in IgAN patients. Systemic glucocorticoids, though associated with significant proteinuria reduction, are usually rapidly tapered and discontinued to avoid significant systemic toxicity and the patients are eventually continued on traditional RAAS inhibition as well as Cellcept for maintenance in some cases.
- |||||||||| Tarpeyo (budesonide) / Calliditas, Stada
NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL (SUN-036; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_855;
Systemic glucocorticoids, though associated with significant proteinuria reduction, are usually rapidly tapered and discontinued to avoid significant systemic toxicity and the patients are eventually continued on traditional RAAS inhibition as well as Cellcept for maintenance in some cases. Nefecon is a novel, oral, targeted-release capsule formulation of budesonide, designed to treat IgAN by downregulating the production of pathogenic IgA1 antibody production at the source (i.e., the Peyer's patch
- |||||||||| Filspari (sparsentan) / Travere Therap
TRF-BUDESONIDE AND SPARSENTAN AS AN INITIAL THERAPY FOR PRIMARY IgA NEPHRITIS (SAT-094; Exhibition Hall and Main Foyer) - Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_841;
Though supportive therapy is the backbone of treatment for all patients with IgAN, most of these patients also do benefit from simultaneous treatment with other medications depending on histological features on biopsy and other co-existing risk factors. Sparsentan, a selective antagonist of the angiotensin II receptor as well as endothelin 1 receptor, recently received FDA approval for proteinuria reduction in IgAN patients at risk of rapid disease progression.
- |||||||||| Zeposia (ozanimod) / BMS, Rinvoq (upadacitinib) / AbbVie
Prescribing Patterns of Novel Oral Therapies for Ulcerative Colitis in a Large Integrated Delivery Network () - Mar 8, 2024 - Abstract #ISPOR2024ISPOR_344;
Our findings suggest that budesonide may be considered as an adjunctive therapy. Of the 71 patients (mean age, 38 years old; 32 [45.1%] female) with UC, 50 patients (64.3%) were prescribed tofacitinib citrate, 22 patients (28.6%) prescribed upadacitinib, and 6 patients (7.1%) prescribed ozanimod hydrochloride...Prior to initiation of novel oral therapies, 26.7% of patients were on TNF-alpha inhibitors (TNFi), 22.5% on DMARD
- |||||||||| prednisone / Generic mfg., budesonide / Generic mfg., mycophenolate mofetil / Generic mfg.
Journal: Refractory IgA Nephropathy: A Challenge for Future Nephrologists. (Pubmed Central) - Feb 28, 2024
Despite these therapies, some patients have a disease refractory to treatment, defined as individuals that present a 24 h urinary protein persistently >1 g after at least two rounds of regular steroids (methylprednisolone or prednisone) and/or immunosuppressant therapy (e.g., mycophenolate mofetil), or who do not tolerate regular steroids and/or immunosuppressant therapy. The aim of this Systematic Review is to revise the current literature, using the biomedical database PubMed, to investigate possible therapeutic strategies, including SGLT2 inhibitors, endothelin receptor blockers, targeted-release budesonide, B cell proliferation and differentiation inhibitors, fecal microbiota transplantation, as well as blockade of complement components.
- |||||||||| Noxafil (posaconazole) / Merck (MSD)
Journal: Cushing syndrome and tertiary adrenal insufficiency from prolonged concomitant use of budesonide and posaconazole. (Pubmed Central) - Feb 26, 2024
However, concomitant use of posaconazole and voriconazole, inhibitors of CYP3A4 commonly used as antifungal prophylaxis in allograft patients receiving immunosuppression, can lead to substantial systemic steroid exposure. This paper describes a case of severe iatrogenic Cushing syndrome and tertiary adrenal insufficiency because of this interaction, highlighting the necessity for improved awareness of this phenomenon.
- |||||||||| budesonide / Generic mfg.
Review, Journal: A Literature Review of Microscopic Colitis. (Pubmed Central) - Feb 26, 2024
Although budesonide is an effective treatment in most cases, budesonide-refractory MC represents a significant clinical challenge. Therefore, immunomodulators and biologics are now well-thought to be the second-line choice for treatment.
- |||||||||| budesonide / Generic mfg.
Trial completion date, Trial primary completion date: Predicting Post Extubation Stridor After Maxillomandibular Fixation (clinicaltrials.gov) - Feb 15, 2024
P=N/A, N=62, Recruiting,
The study suggests that an optimized single-layer coating, incorporating pH and time-dependent polymers, holds promise for consistently delivering budesonide to the descending colon. Trial completion date: Dec 2023 --> Jun 2025 | Trial primary completion date: Nov 2023 --> Feb 2025
- |||||||||| Filspari (sparsentan) / Travere Therap, CSL Behring, Tarpeyo (budesonide) / Calliditas, Stada
Review, Journal: Novel Treatment Paradigms: Primary IgA Nephropathy. (Pubmed Central) - Feb 12, 2024
Advancing insights into the pathophysiology of IgAN, including the roles of the mucosal immune system, B-cells, the complement system, and the endothelin system have driven development of therapies that target these factors. This review outlines current, recently approved, and emerging therapies for IgAN.
|
